CL2023003441A1 - Métodos de tratamiento de trastornos relacionados con la mitocondria - Google Patents
Métodos de tratamiento de trastornos relacionados con la mitocondriaInfo
- Publication number
- CL2023003441A1 CL2023003441A1 CL2023003441A CL2023003441A CL2023003441A1 CL 2023003441 A1 CL2023003441 A1 CL 2023003441A1 CL 2023003441 A CL2023003441 A CL 2023003441A CL 2023003441 A CL2023003441 A CL 2023003441A CL 2023003441 A1 CL2023003441 A1 CL 2023003441A1
- Authority
- CL
- Chile
- Prior art keywords
- methyl
- methods
- related disorders
- mitochondria
- dinitrophenoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163191321P | 2021-05-20 | 2021-05-20 | |
| US202163222841P | 2021-07-16 | 2021-07-16 | |
| US202263307515P | 2022-02-07 | 2022-02-07 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2023003441A1 true CL2023003441A1 (es) | 2024-05-10 |
Family
ID=82020295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2023003441A CL2023003441A1 (es) | 2021-05-20 | 2023-11-20 | Métodos de tratamiento de trastornos relacionados con la mitocondria |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250177353A1 (https=) |
| EP (1) | EP4340829A1 (https=) |
| JP (1) | JP2024521709A (https=) |
| KR (1) | KR20240021827A (https=) |
| AU (1) | AU2022275935A1 (https=) |
| BR (1) | BR112023024146A2 (https=) |
| CA (1) | CA3219548A1 (https=) |
| CL (1) | CL2023003441A1 (https=) |
| GE (1) | GEAP202416398A (https=) |
| IL (1) | IL308669A (https=) |
| JO (1) | JOP20230298A1 (https=) |
| MX (1) | MX2023013688A (https=) |
| TW (1) | TW202313010A (https=) |
| WO (1) | WO2022246039A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023150759A1 (en) * | 2022-02-07 | 2023-08-10 | Rivus Pharmaceuticals, Inc. | Methods of weight loss in a subject with elevated hba1c |
| TW202515545A (zh) * | 2023-08-10 | 2025-04-16 | 大陸商深圳君聖泰生物技術有限公司 | ２，４－二硝苯酚之衍生物以及前藥、以及其組成物以及方法 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1098641B1 (en) | 1998-07-27 | 2016-04-27 | St. Jude Pharmaceuticals, Inc. | Chemically induced intracellular hyperthermia |
| PT3565806T (pt) | 2017-01-06 | 2022-05-19 | Rivus Pharmaceuticals Inc | Novos derivados de fenilo |
-
2022
- 2022-05-19 WO PCT/US2022/029992 patent/WO2022246039A1/en not_active Ceased
- 2022-05-19 KR KR1020237043901A patent/KR20240021827A/ko active Pending
- 2022-05-19 BR BR112023024146A patent/BR112023024146A2/pt unknown
- 2022-05-19 AU AU2022275935A patent/AU2022275935A1/en active Pending
- 2022-05-19 IL IL308669A patent/IL308669A/en unknown
- 2022-05-19 JP JP2023571818A patent/JP2024521709A/ja active Pending
- 2022-05-19 GE GEAP202416398A patent/GEAP202416398A/en unknown
- 2022-05-19 MX MX2023013688A patent/MX2023013688A/es unknown
- 2022-05-19 US US18/562,560 patent/US20250177353A1/en active Pending
- 2022-05-19 EP EP22729956.7A patent/EP4340829A1/en active Pending
- 2022-05-19 CA CA3219548A patent/CA3219548A1/en active Pending
- 2022-05-20 TW TW111118998A patent/TW202313010A/zh unknown
-
2023
- 2023-11-19 JO JOJO/P/2023/0298A patent/JOP20230298A1/ar unknown
- 2023-11-20 CL CL2023003441A patent/CL2023003441A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4340829A1 (en) | 2024-03-27 |
| KR20240021827A (ko) | 2024-02-19 |
| JP2024521709A (ja) | 2024-06-04 |
| JOP20230298A1 (ar) | 2023-11-19 |
| US20250177353A1 (en) | 2025-06-05 |
| TW202313010A (zh) | 2023-04-01 |
| WO2022246039A1 (en) | 2022-11-24 |
| AU2022275935A1 (en) | 2023-12-07 |
| BR112023024146A2 (pt) | 2024-01-30 |
| CA3219548A1 (en) | 2022-11-24 |
| MX2023013688A (es) | 2024-02-27 |
| GEAP202416398A (en) | 2024-01-25 |
| IL308669A (en) | 2024-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023003441A1 (es) | Métodos de tratamiento de trastornos relacionados con la mitocondria | |
| DE60327771D1 (de) | Glp-1 und behandlungsmethode für diabetes | |
| ATE450269T1 (de) | Peptid pyyä3-36ü zur behandlung von stoffwechselkrankheiten | |
| NO20053678L (no) | Kombinasjonsterapi for behandling av immuninflammatoriske forstyrrelser | |
| EA202193190A1 (ru) | Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов | |
| AR114392A1 (es) | Tratamiento de pacientes con enfermedad de fabry clásica | |
| MX2025005378A (es) | Metodos para el tratamiento de enfermedades cardiovasculares | |
| ATE414522T1 (de) | Verfahren zur behandlung von akuter und durch übermässige beanspruchung verursachter zerrung und verstauchung mit hyaluronsäure | |
| CO2022015018A2 (es) | Métodos y medios para modificar la hemodinámica en infecciones | |
| CY1111783T1 (el) | Θεραπεια συνδυασμου διαταραχων κατωτερης ουροποιητικης οδου με 2 προσδεματα και μη στεροειδες αντιφλεγμονωδες φαρμακο | |
| IL318374A (en) | Methods of administering nalbuphine | |
| BR0310061A (pt) | Métodos para o tratamento de doenças e condições respiratórias com um inibidor seletivo da inos e um inibidor da pde e suas composições | |
| AR022116A1 (es) | Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa | |
| MA56386B1 (fr) | Polythérapie comprenant de l'acétyl-leucine et du miglustat pour le traitement d'une maladie lysosomale | |
| JPH02180828A (ja) | 男性不能症の治療用物質 | |
| MX2023003258A (es) | Tratamiento de enfermedades mediadas por nf-kb. | |
| BR0311180A (pt) | Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos | |
| Kumar et al. | An observational study to compare the outcome of local steroid injections and ultrasonic wave therapy in frozen shoulder patients | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| CN107233417A (zh) | 一种治疗糖尿病的外用中药 | |
| MX2025013157A (es) | Tratamiento de afecciones inflamatorias que comprende imu-856 | |
| TW202611065A (zh) | pUDK-HGF注射液的用途 | |
| ATE495750T1 (de) | Sulfatide zur behandlung von autoimmunkrankheiten | |
| WO2025264860A3 (en) | Methods of treating post-covid airway disease | |
| Seifi et al. | Effect of intravenous regional anesthesia with spinal block on foot surgeries: A double-blinded randomized clinical trial |